<span item_type="fundamental" item_id="85d5da3fc468bce6c50779c24ccef0f7" counter_id="ST/US/FBIOP" env="prod"></span><span item_type="announcement" item_id="549447141867587073" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 16.41 M.</p><p>EPS: As of FY2025 Q2, the actual value is USD 0.45.</p><p>EBIT: As of FY2025 Q2, the actual value is USD -36.47 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Journey Medical Corporation (JMC)</strong>: Net product revenue was $15.0 million for the three months ended June 30, 2025, compared to $14.9 million for the same period in 2024. For the six months ended June 30, 2025, net product revenue was $28.1 million, compared to $27.9 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025011570/fbio-20250630x10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Loss from Operations</strong>: The consolidated loss from operations was $36.5 million for the three months ended June 30, 2025, compared to $27.8 million for the same period in 2024. For the six months ended June 30, 2025, the loss from operations was $58.8 million, compared to $64.4 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025011570/fbio-20250630x10q.htm"></span></li><li><strong>Research and Development Expenses</strong>: R&amp;D expenses decreased to $8.1 million for the three months ended June 30, 2025, from $12.7 million in 2024. For the six months ended June 30, 2025, R&amp;D expenses were $12.1 million, down from $37.5 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025011570/fbio-20250630x10q.htm"></span></li><li><strong>Selling, General and Administrative Expenses</strong>: These expenses increased to $38.8 million for the three months ended June 30, 2025, from $20.8 million in 2024. For the six months ended June 30, 2025, these expenses were $64.4 million, up from $38.8 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025011570/fbio-20250630x10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: For the six months ended June 30, 2025, net cash used in operating activities was $47.1 million, compared to $47.2 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025011570/fbio-20250630x10q.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: For the six months ended June 30, 2025, net cash provided by financing activities was $56.7 million, compared to $42.1 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025011570/fbio-20250630x10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Gain from Deconsolidation of Subsidiary</strong>: A gain of $27.1 million was recognized from the deconsolidation of Checkpoint due to its acquisition by Sun Pharma in May 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025011570/fbio-20250630x10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: Fortress Biotech plans to continue focusing on acquiring and advancing assets to enhance long-term value through product revenue, equity holdings, and dividend and royalty revenue streams. The company aims to leverage its network to identify promising products for acquisition and development.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025011570/fbio-20250630x10q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is exploring strategic partnerships and collaborations to support research and development, including joint ventures and out-licensing opportunities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025011570/fbio-20250630x10q.htm"></span></li></ul>

Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 10-Q: FY2025 Q2 Revenue: USD 16.41 M